ArticleCureus2025
A Case of Asymptomatic Cronkhite-Canada Syndrome Diagnosed by Endoscopic and Pathological Findings.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: A case of Cronkhite-Canada syndrome associated with sigmoid colon cancer and early esophageal cancer.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cronkhite-Canada syndrome (CCS) is a rare, non-hereditary disease characterized by specific symptoms, ectodermal abnormalities, endoscopic findings, and pathological examination. We report a unique case of a 39-year-old man with suspicious CCS. Although the blood test showed iron-deficiency anemia and hypoalbuminemia, he exhibited no symptoms, including those related to CCS itself and anemia and hypoalbuminemia. According to the result of endoscopic and pathological examination, he was diagnosed with possible CCS. While following the patient's medical course, the serum albumin level gradually declined. Six months after the diagnosis, oral corticosteroid therapy was initiated to prevent disease progression. Consequently, the patient achieved a favorable clinical course without developing any symptoms. This case highlights the importance of considering CCS even in the absence of typical symptoms and suggests that therapeutic intervention may be beneficial even in asymptomatic presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.